bioMérieux: Invest Securities raises target price
(CercleFinance.com) - Invest Securities has reiterated its "buy" rating on bioMérieux shares, having increased its target price from 133 euros to 144 euros, after updating its estimates for the in vitro diagnostics group (2021-23 EPS raised by +3%/+1%/+1% respectively).
Given the high epidemic intensity since the beginning of November and the likely spread of the Omicron variant, the broker has raised its Q4 estimate for the molecular diagnostics division (-3% versus -15% previously).
Invest Securities has also raised its H2 EBITA margin guidance by 40 basis points. Given uncertainties, at this stage analysts are maintaining their estimates for 2022, which they say could be conservative.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.